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Abstract 
 The lysine methyltransferase NSD3, which belongs to a family of histone 
H3 lysine 36 methyltransferases that are conserved among vertebrates and 
overexpressed in many cancers, is independently required for both neural crest 
cell specification and migration in the developing chick embryo. Since 
cytoplasmic protein lysine methylation is also required for neural crest cell 
migration in chick, one possibility is that NSD3 methylates non-histone 
substrates. To test this hypothesis, it is necessary to purify NSD3 protein that is 
active in a methyltransferase assay, in order to evaluate candidate substrates 
individually and on protein arrays. In this thesis, I describe a detailed method for 
high-yield purification of a chick NSD3 catalytic fragment, followed by a chick 
NSD3 methyltransferase assay with which to test for activity on polynucleosomes 
and/or candidate non-histone substrates. 
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Chapter 1 
Introduction 
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1.1 The in vitro methyltransferase assay is an indispensable test of KMT 
function and/or substrate specificity  
Ever since the discovery of the evolutionarily conserved protein lysine 
methyltransferase Su(var)3-9, Enhancer-of-zeste and Trithorax (SET) domain in 
Drosophila (Tschiersch et al., 1994), and the realization that histone lysine 
methylation profoundly influences the regulation of eukaryotic gene expression 
(Lachner and Jenuwein, 2002), proteins containing a SET domain have been 
almost axiomatically referred to as ‘histone methyltransferases’ (Rea et al., 2000; 
Kondo, 2014). However, since many SET domain-containing lysine 
methyltransferases such as NSD1, G9a, EZH2, SET7/9 and many others have 
also been shown to methylate non-histone proteins (Huang and Berger, 2008; Lu 
et al., 2010), the term is something of a misnomer that presupposes a singular 
biological role for SET enzymes. As evidence builds to indicate that non-histone 
protein methylation affects target subcellular localization, stability, and 
interactions with other proteins or nucleic acids (Lee and Stallcup, 2009), the 
more appropriately generalized terms ‘protein lysine methyltransferase’ or simply 
‘lysine methyltransferase’ (KMT), have come into more common usage (Clark, 
2013; Lanouette, 2014). Given this emerging awareness, the development of 
experimental tools to characterize the substrate specificity and full functionality of 
each KMT is becoming increasingly paramount. 
A fundamental means to test putative substrates of any SET domain-
containing KMT is an in vitro methyltransferase (MTase) assay. Typically, this 
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consists of incubating a KMT with the radiolabeled methyl donor S-adenosyl-L- 
[methyl-3H] methionine (3H-SAM) and substrate(s), then performing SDS-PAGE, 
Western blot, and autoradiography. Most frequently, MTase assays are used to 
evaluate individual candidate substrates, identify target lysines through 
mutational analysis, and/or define MTase activity for SET domain-containing 
KMTs, from fruit fly E(Z) to human NSD1 (Müller et al., 2002; Kudithipudi et al., 
2014). These studies can eventually yield not only an in-depth understanding of a 
KMT and its preferred substrates in isolation, but also variation in activity (and by 
extension, biological function) based on association with other endogenous 
factors, which are often necessary for maximal MTase activity in vitro (Ketel et 
al., 2005). 
When a MTase assay is adapted for a broader scale using arrays, many 
proteins can be simultaneously evaluated as potential substrates. For instance, 
the human KMT G9a and 3H-SAM were applied to a peptide array based on 
single variants of histone H3 N-terminal sequence, yielding 2 strongly methylated 
candidate non-histone targets (Rathert et al., 2008). More recently, an improved 
substrate array consisting of over 9,000 human proteins expressed in insect cells 
and printed in duplicate (ProtoArray®), was used to find over 100 novel non-
histone targets of SETD6 (Levy et al., 2011). Certainly, whether candidate 
substrates are arrayed for an unbiased assessment of KMT specificity, or tested 
in isolation for detailed biochemical analyses, a methyltransferase assay is an 
essential tool to investigate KMT non-histone protein targets. 
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1.2 The NSD family of lysine methyltransferases 
A group of closely-related KMTs of particular relevance to this thesis are 
the nuclear receptor-binding, SET domain-containing (NSD) family of enzymes, 
which are conserved throughout the vertebrate lineage, and are oncogenic when 
overexpressed in humans (Lucio-Eterovic and Carpenter, 2011; Morishita and di 
Luccio, 2011; ). Actually, NSD1 is the only one of these known to bind to nuclear 
receptors (Huang et al., 1998), but the official names of the others are 
cumbersome (WHSC1, WHSC1L1), so I will henceforth refer to them as NSD2 
and NSD3.  
All three of these proteins are highly similar within a 700 amino acid region 
that includes the core SET domain and the associated pre-SET and post-SET 
domains (Angrand 2001), and share several protein-protein and/or protein-DNA 
interaction domains. Despite an initial controversy over the histone lysine residue 
specificity of the human NSDs (Kim et al., 2006), it was thoroughly investigated 
using bacterially-expressed 300 amino acid catalytic NSD fragments and 
different types of histone substrates, revealing that human NSDs are histone H3 
lysine 36 (H3K36) dimethylases on nucleosomes (Li et al., 2009). In that study, 
the Reinberg group also showed full-length NSD2 had the exact same H3K36 
specificity on nucleosomes, even when purified in complex with endogenous 
factors from HT1080 human fibrosarcoma cells.  
Recently, human NSD family enzyme kinetics were characterized in detail, 
and it was found that a shared basic region within the post-SET domain is largely 
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responsible for the different specificities on various histone substrates (Allali-
Hassani et al., 2014). H3K36 specificity on nucleosomes was confirmed using 
nearly identical catalytic fragments as before, while a set of truncations were 
found to reduce or abolish activity. Thus, at least for the human NSD family, it 
appears substrate specificity is retained regardless of whether full-length enzyme 
or the catalytic fragment described in (Li et al., 2009) is used in a MTase assay.   
In addition to all three human NSDs, homologs found in higher eukaryotes 
share this H3K36 dimethylation specificity on chromatin. In Drosophila, H3K36 
dimethylation by the KMT dMes-4 is thought to play a role in nucleosome 
positioning and RNA splicing (Bell et al., 2007; Lhoumaud et al., 2014). The C. 
elegans NSD homolog MES-4 is also required for H3K36 dimethylation, and its 
histone H3 specificity is retained in an in vitro MTase assay using bacterially-
expressed enzyme (Bender et al., 2006).  
Strikingly, the NSD family is also highly conserved throughout the 
vertebrate lineage, and especially mammals and birds (NCBI HomoloGene). 
Thus, it is imperative that the complete in vivo function of these KMTs is 
investigated using robust experimental tools, such as are available in mice and 
chick. 
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1.3 Chick NSD3 is an attractive candidate for non-histone target discovery 
Interestingly, we found two chick KMTs in a screen for factors involved in 
the vertebrate-specific process of neural crest development: NSD3 and SETD2 
(Gammill and Bronner-Fraser, 2002; Adams et al., 2008). Additionally, we also 
found other components of the SAM-dependent in vivo methylation cycle, 
including DNMT3B, KDM5A and SAHH. Given these results, our lab has been 
working to understand the full impact of methylation on neural crest development. 
This is especially crucial because prenatal supplementation with the methylation-
associated compound folic acid is widely used to prevent neural tube and neural 
crest-related birth defects, yet the mechanistic basis for this effect remains 
unknown (Wehby and Murray, 2011). Moreover, efforts to understand 
methylation are urgently needed because both broad-spectrum and selective 
methylation inhibitors are used as chemotherapy agents (though none 
specifically inhibit the NSDs; Kaniskan et al., 2014).  
 Indeed, since NCCs are a migratory, multipotent and highly invasive 
mesenchymal cell type, similar in both gene expression and behavioral 
phenotype to metastatic cancers (Gupta et al., 2005; Thiery et al., 2009), 
elucidating NSD3's vertebrate-specific functional role in migratory cells could 
have far-reaching significance. Regarding neural crest-derived metastatic 
melanoma in particular, there is increasing evidence to support the model that 
oncogenesis involves reactivation of the NCC embryonic transcriptional program 
(Bailey et al., 2012).   
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 While NSD3's role as a transcription-coupled chromatin modifier is 
beginning to emerge (Fang et al., 2010), multiple lines of evidence suggest 
NSD3-mediated non-histone protein methylation could regulate NCC migration in 
a novel manner, independent of its role as a H3K36 dimethylase. First, taking 
note of the comparatively weak H3K36 activity of both NSD1 and NSD3 in vitro 
(Li et al., 2009), and that NSD1 is known to methylate the non-histone p65 
subunit of NF-κB (Lu et al., 2010), it is reasonable to think NSD3 also methylates 
non-histone substrates. Furthermore, not only have we found that NSD3 is 
required for both NCC specification and migration, and that these roles are 
distinct in developmental time (Jacques-Fricke and Gammill, 2014), we find 
NSD3 localized in the cytoplasm via immunostaining in both chick NCCs and 
human C8161 melanoma cells (data not shown). Even more strikingly, we find 
that methylation of 6 lysine residues of EF1α1, an abundant cytoplasmic 
translational elongation factor found at the leading edge of motile cells 
(Condeelis and Singer, 2005), is required for NCC migration in chick (Vermillion 
et al., 2014).   
 Clearly, establishing a chick NSD3 methyltransferase assay to assess 
candidate non-histone substrates, whether singly in a tube or affixed to a 
ProtoArray®, is a critical step toward investigating the role of NSD3 methylation 
in both neural crest development and related cancers. 
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Chapter 2 
An optimized procedure for high-yield purification 
 of catalytically active chick NSD3-SET 
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2.1 Procedure notes & overview 
2.1.1 Notes about the procedure 
The steps contained in this procedure have been adapted and assembled 
from a variety of sources, including the published study revealing human NSD 
family H3K36 specificity on DNA-wrapped nucleosomes (Li et al., 2009), Ni-NTA 
Superflow column product literature (Qiagen), and the technical expertise of 
fellow University of Minnesota Developmental Biology Center lab members (see 
Acknowledgements) and Life Technologies Technical Staff.  
I originally purified 3xFLAG-tagged full-length chick NSD3 from a 
baculoviral insect cell system, but found early preparations to be inactive. Rather 
than troubleshoot that system, and/or express full-length NSD3 in human cells 
and attempt to co-purify endogenous complexes necessary for robust activity (as 
was performed for full-length human NSD2; Li et al., 2009), I opted for the 
relatively expedient method of obtaining catalytically active chick NSD3 for use in 
a MTase assay; that is, a bacterially-expressed 300 amino acid NSD3 catalytic 
fragment as per (Li et al., 2009). This fragment corresponds with 95% identity1 to 
amino acids 1021-1320 of human NSD3, and although it includes several 
domains in addition to the core SET domain, I will henceforth refer to it as NSD3-
SET. 
A key difference from the Reinberg lab NSD3-SET purification method 
was that we chose to affix an N-terminal 6xHis-tag to NSD3-SET and perform Ni-
NTA column purification, rather than a GST-tag with glutathione columns. This 
decision was mainly due to the very small size of the 6xHis-tag, which we 
assumed to be less likely to cause undesirable effects on NSD3-SET purification 
and/or MTase activity, versus the 26 kDa GST-tag. 
Imidazole competes with the binding of the 6xHis tag to the Ni-NTA 
column, and is therefore used at lower concentrations to reduce the binding of 
                                                
1 (NCBI BLAST alignment: G. gallus XP_001232891.1 residues 1021-1320 vs. H. 
sapiens NP_075447.1) 
2 Alternatively, storage of NSD3-SET purified preparations in liquid N2 may extend the 
   10 
 
histidine-rich contaminating proteins, and for elution at 250 mM. However, 250 
mM imidazole is inhibitory to KMT activity (Life Technologies Technical Staff, 
personal communication), and therefore buffer exchange must be performed 
prior to using the purified NSD3-SET in a methyltransferase (MTase) assay. 
Typically, an overnight dialysis at 4°C is performed, then the eluate is 
concentrated at room temperature using ‘spin columns’ or centrifugal filter 
devices (CFDs). However, since both dialysis membranes and CFDs have a 
molecular weight cutoff rating, I tried to shorten the overall time for the procedure 
by omitting the overnight dialysis, in favor of simply performing the buffer 
exchange within the CFD itself. This is accomplished by adding fresh imidazole-
free buffer to the concentrated sample, spinning again, and repeating this for 
several rounds. Surprisingly, though this method slightly increases room-
temperature sample handling time within the CFD, it did not result in any 
noticeable adverse effects. In fact, opting for MicroSep™ CFD-mediated buffer 
exchange improved sample purity while maintaining NSD3-SET activity in the 
downstream MTase assay (Fig. 3, Fig. 4). 
A key concern with native, non-denaturing protein purification is 
maintaining solubility. Often a bacterially-expressed protein that is normally 
soluble can become entrapped in inclusion bodies, and precipitate along with 
cellular debris when clearing the lysate via centrifugation. I determined that 
reducing the culture temperature to 17°C immediately before IPTG induction (as 
in Li et al., 2009) maintained NSD3-SET solubility, likely due to slowing the rate 
of protein expression and preventing its sequestration within inclusion bodies. 
 Later in the procedural workflow, while performing CFD-mediated buffer 
exchange, another issue with NSD3-SET solubility arose. I resolved this by 
removing glycerol from the elution buffer, which was also advantageous for other 
reasons. First, glycerol is inhibitory to MTase activity at assay concentrations 
above ~15% (Aswathy Rai, personal communication), and so a limited amount 
can be added to a MTase assay. When NSD3-SET is prepared without glycerol, 
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a slightly less concentrated sample can be tested, and/or an increased amount of 
enzyme can be added to the assay. Second, because Life Technologies screens 
ProtoArrays® using a Tris-based reaction buffer without glycerol, glycerol-free 
purification conforms to their standards. 
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2.1.2 Overview of the procedure 
  
I. A pET24b+ expression plasmid containing N-terminally 6xHis-tagged 
chick NSD3-SET is freshly transformed into BL21 (DE3) E. Coli cells.  
II. Starter cultures are grown from single colonies at 37°C, and expanded to 
1.5 L total volume. Near the end of log-phase growth, the temperature is 
reduced to 17°C, and NSD3-SET is expressed under IPTG induction for 
18 hours. 
III. Cells are harvested by centrifugation, and pellets are stored at -80°C for a 
minimum of 1 hour. 
§ PAUSE POINT: Pellets may be stored at -80° C for 4 days, or possibly 
longer, but catalytic activity may suffer. 
IV. Robust expression of NSD3-SET is confirmed via SDS-PAGE & 
Coomassie staining, comparing uninduced vs. induced crude cell lysates. 
V. The NSD3-SET expression cultures are resuspended in low-imidazole 
buffer (NPI-10) at 4°C and lysed with a pre-chilled French press. 
VI. The cell lysate is ‘cleared’ via centrifugation at 4°C, and further cleared 
with 5 µm syringe filters, removing particulates which may clog the Ni-NTA 
column. 
VII. Still at 4°C, NSD3-SET contained in the cell lysate is bound to an 
equilibrated Ni-NTA Superflow column, washed with buffers of increasing 
stringency (NPI-20 and NPI-80) and eluted with 250 mM imidazole. 
VIII. The samples are brought to room temperature and buffer exchange is 
performed within CFDs, using several rounds of centrifugation and 
addition of fresh imidazole-free buffer, and a final centrifugation to 
concentrate the sample.  
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IX. Aliquots of the purified, concentrated NSD3-SET preparation are snap-
frozen in liquid N2 and stored2 at -80°C, save ~5 µl kept on ice for quality 
control analysis. 
§ PAUSE POINT: Purified KMT aliquots may be stored long-term at -80°C; 
however, it was determined that NSD3-SET activity rapidly declines within 2-4 
weeks. Thus, quality control testing and downstream experiments (i.e., 
ProtoArray®) should be performed within one week or less, if possible. 
X. The concentration of the NSD3-SET preparation is determined with the 
Qubit Protein Assay.3 
XI. The purity of the NSD3-SET preparation is assessed with SDS-PAGE, 
followed by Coomassie staining. 
XII. NSD3-SET catalytic activity is tested with the MTase assay using 
polynucleosome control substrate. NSD3-SET methylation of any purified 
candidate substrates in-hand, or complex mixtures of chick proteins (i.e., 
tissue/cell lysates) may be tested simultaneously also. 
 
 
 
 
 
 
                                                
2 Alternatively, storage of NSD3-SET purified preparations in liquid N2 may extend the 
half-life of its MTase activity, though this remains untested. 
3  Though a Bradford protein assay may be used, the Qubit® Protein Assay requires as 
little as 1 µl of purified sample to reliably determine concentration. 
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2.2 Materials 
2.2.1 Reagents  
o Chick NSD3-SET catalytic fragment cDNA, cloned with an N-terminal 
6xHis tag into pET-24b+ E. Coli expression vector, mini-prepped and 
sequence-verified. 
o Kanamycin 1000X stock solution, 37.5 mg/mL 
o Super LB: 2X LB mix + 2.0 g glucose per liter 
o Sodium phosphate imidazole (NPI) buffers:  
• NPI-10: 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole 
• NPI-20: 50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole 
• NPI-80: 50 mM NaH2PO4, 300 mM NaCl, 80 mM imidazole 
• NPI-250: 50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole 
o Imidazole-free KMT storage buffer: 50 mM Tris pH 9.0, 5 mM MgCl2, 1 
mM DTT (Life Technologies recommended) 
o Protease inhibitor stock solutions 
• 104 base PIs (10,000x base protease inhibitors): In 1 mL DMSO, 
add 10 mg leupeptin (Sigma L2023-10MG), 10 mg chymostatin 
(Sigma C7268-5MG, Qty. 2), 10 mg pepstatin A (Sigma P4265-
5MG, Qty. 2) and 5 mg antipain (Sigma A6191-5MG). Aliquot 100 
µl per tube and store at -20°C. 
• PMSF 100 mM (phenylmethanesulfonyl fluoride, Sigma P7626-
250MG4): Dissolve 0.1742 g in 10 mL isopropanol. Aliquot 1 mL per 
tube and store at -20°C. 
• DTT 1 M (dithiothreitol, Sigma D97795): Dissolve 1.5425 g in 10 mL 
0.01 M sodium acetate, pH 5.2. Filter sterilize, aliquot 1 mL per 
tube and store at -20°C. 
                                                
4 Gammill Lab location: room temperature dessicator. 
5 Gammill Lab location: dessicator in deli 4°C. 
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• TLCK 50 mg/mL (Nα-Tosyl-L-lysine chloromethyl ketone 
hydrochloride, Sigma A1153-10MG): Add 2 mL HCl 1 mM to 100 
mg bottle, aliquot 1 mL per tube and store at -20°C. 
• Benzamidine 0.1 M (Sigma 434760-5G): Dissolve in sterile H2O, 
aliquot 1 mL per tube and store at -20°C. 
• Aprotinin 10 mg/mL (Sigma A1153-10MG): Add 1 mL sterile H2O to 
bottle, aliquot 100 µl per tube and store at 4°C. 
o GelCode™ Blue Safe Coomassie protein stain (ThermoFisher 24594) 
o Qubit® Protein Assay Kit (Life Technologies Q3321) 
o 2X MTase assay buffer (Simon Lab): 
24 mM HEPES pH 7.9 
0.48 mM EDTA 
24% glycerol 
8 mM DTT 
5 mM MgCl2 
60 mM KCl 
o Histone H3-specific positive control KMT, e.g., Drosophila PRC (Simon 
Lab) 
o Amido Black Staining Solution 2X (Sigma A8181-1EA) 
o EN3HANCE™ autoradiography spray (Perkin Elmer 6NE970C) 
o Immobilon™-P transfer membrane (Sigma P2938-1ROL) 
o Polynucleosomes (1 mg/mL) purified from HeLa cells (Simon Lab; Biovest 
International, Inc.) 
o Towbin transfer buffer with SDS (25 mM Tris, 192 mM glycine, 10% 
methanol, and 0.01% SDS) 
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2.2.2 Equipment 
o Incubated/refrigerated orbital shaker6 (Forma™ 4580) or equivalent 
o Spectrophotometer, for taking OD600 readings 
o Incubated centrifuge7 (Beckman J2-MC) or equivalent 
o FRENCH® pressure cell press8 (Thermo Electron FA-078) or equivalent 
o Acrodisc® 32 mm Syringe Filter with 5 µm Supor® Membrane (Pall Corp. 
4650) 
o PureLink™ Nucleic Acid Purification Rack (Life Technologies K2100-13) 
or equivalent  
o Ni-NTA Superflow Column (Qiagen 30622). Store upright at 4°C. 
o Pipet-Aid® serological pipette controller (USA Scientific 4440-1000) or 
equivalent 
o MicroSep™ Advance Centrifugal Device, 30 kDa molecular weight cutoff 
(Pall Corp. MCP03046)9. Store at RT. 
o Qubit® 2.0 Flourometer (Life Technologies Q32866) 
o Tritium-labeled S-adenosyl-L-[methyl-3H] methionine 
o Scintillation fluid and scintillation vials 
o Lift-Away decontaminant (RPI International 114002) 
 
 
 
 
                                                
6 Large shaker in Moos 5-140, behind door near Kawakami Lab cryostat 
7 Centrifuge in Bardwell Lab Moos 5-145 
8 Lange Lab French press components are stored at 4°C in MCB 7-159 
9 Amicon® Ultra-4 30 kDa MW cutoff (Millipore UFC803008) was compared in parallel 
and found to be inferior to the MicroSep™ CFD.	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2.3 Procedure: NSD3-SET purification 
2.3.1 Bacterial culture and NSD3-SET expression 
 
Ø CRITICAL: Start each purification from a freshly-transformed culture, as 
the expression plasmid w/insert is unstable in BL21 cells. 
1. Transform expression plasmid into BL21 (DE3) E. Coli competent cells.  
i. Thaw competent BL21 cells on ice, up to 30 minutes. 
ii. Add 25 µl cells to 1 µl plasmid (assuming ~200 ng/µl DNA 
concentration) and gently pipette up and down 2-3X to mix. 
iii. Incubate 30 minutes on ice. 
iv. Heat shock at 42°C for 1 minute, then incubate on ice for 2 minutes. 
v. Add 475 µl SOC at RT. 
vi. Recover 1-2 hours at 37°C w/shaking ~250 rpm. 
vii. Streak out 50 µl of each transformation on an LB-kan plate using the 
micropipette tip or a sterile toothpick, and incubate O/N at 37°C. 
Ø CRITICAL: BL21 cells are high-efficiency; spreading the full reaction will 
result in colony overgrowth. 
2. Inoculate several pre-warmed 3 mL LB-kan starter cultures by picking single 
colonies. Incubate at 37°C w/shaking ~250 rpm for 4 hours. 
3. While the starter cultures are incubating, pre-warm the large 
incubated/refrigerated orbital shaker to 37°C. Adjust the setting such that 
the thermometer inside actually reads 37°C (i.e., incubator setting of 
~35.9°C). 
4. Prepare two bottles of Super LB (750 mL each) by autoclaving, and add 750 
µl kanamycin (final concentration 37.5 µg/mL). Save 1 mL as a 
spectrophotometer ‘blank’ for OD600 readings. 
5. Pour 750 mL Super LB-kan into two clean, autoclaved 2 L Erlenmeyer 
flasks, and place the culture flasks in the incubated/refrigerated shaker. 
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Allow to equilibrate to 37°C. (Hint: tin foil suffices as a vented culture flask 
cap.) 
6. Inoculate each flask containing 750 mL Super LB-kan with one 3 mL starter 
culture each. Incubate at 37°C w/shaking ~250 rpm for 4 hours. 
7. Begin checking OD600 every 30-60 minutes. Once OD600 reaches 2.2-2.8, 
reduce the incubated/refrigerated shaker temperature setting to 
approximately 15.9°C, such that the thermometer inside the shaker stably 
reads 17°C. 
Ø CRITICAL: Ensure that the temperature inside the culture chamber is 
stable at 17°C before induction of NSD3-SET expression. 
8. Withdraw 0.5-1.0 mL of each culture for a non-induced expression control 
(see 2.3.2). Spin these samples down, remove the media, and save the 
pellets at -20°C. 
9. Induce protein expression by adding 375 µl 1M IPTG to each culture flask 
(final concentration 0.5 mM). Incubate 18 hours at 17°C w/shaking ~250 
rpm. 
10. Just before harvesting cultures, withdraw 0.5-1.0 mL for an induced 
expression control (see 2.3.2). Spin these samples down, remove the 
media, and save the pellets at -20°C. 
11. Harvest cultures by centrifugation at 4°C to pellet the bacterial cells. Spin 
several rounds in two 250 mL plastic bottles with a JA-17 rotor @ 7,000 
rpm, pouring off the media after each spin. Freeze cell pellets at -80°C for a 
minimum of 1 hour. 
§ PAUSE POINT: Cell pellets containing the expressed His-NSD3-SET can 
be stored at -80°C for 4 days, or possibly longer, but catalytic activity may 
suffer. 
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2.3.2 Crude analysis of NSD3-SET expression 
 
12. Thaw cell pellets (from Step 8 and Step 10) and resuspend in 75 µl PBS. 
13. Add 25 µl 4X SDS-PAGE sample buffer w/BME and vortex 30 seconds. 
14. Spin 10 minutes at 12,000 X g. 
15. Boil samples 5-10 minutes in heat block. 
16. Load 16 µl of each sample in a 4-12% polyacrylamide gel, and 
electrophorese at 80V until past the 4% stacking gel, then ~1 hour at 100V. 
17. Remove the gel and wash it in nanopure water, 3 x 5 minutes. 
18. Stain the gel for 1-2 hours with shaking in GelCode Blue Safe Coomassie 
stain. 
19. Destain gel in nanopure water for 2-3 hours to O/N. Folding up a Kimwipe 
and putting it along the inner side of the container helps speed up 
destaining. 
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  5 mL 10 mL 15 mL 20 mL 25 mL 50 mL   
final X For full PI cocktail to given volume, add: stock X 
2X base PIs 1 µl 2 µl 3 µl 4 µl 5 µl 10 µl 10^4 base PIs 
2X aprotinin 5 µl 10 µl 15 µl 20 µl 25 µl 50 µl 10 mg/mL aprotinin 
1 mM benzamidine 5 µl 10 µl 15 µl 20 µl 25 µl 50 µl 1 M benzamidine 
50 µg/mL TLCK 5 µl 10 µl 15 µl 20 µl 25 µl 50 µl 50 mg/mL TLCK 
1 mM DTT10 5 µl 10 µl 15 µl 20 µl 25 µl 50 µl 1 M DTT 
0.4 mM PMSF 20 µl 40 µl 60 µl 80 µl 100 µl 200 µl 100 mM PMSF 
 
Table 1. Volumes of protease inhibitors to add, given frequently used buffer 
volumes 
 
 
 
 
 
                                                
10 The DTT concentration is reduced from 2 mM to 1 mM, which differs from the Simon 
Lab PI cocktail, originally to comply with Ni-NTA Superflow column buffer 
recommendations (Ni-NTA Superflow BioRobot Handbook, Qiagen 09/2002). Later, it 
was discovered that the maximum recommended DTT concentration is actually 10 mM 
(Important Note for Ni-NTA users, Qiagen 05/2008). Regardless, 1 mM DTT was used in 
the PI cocktails for the catalytically active 12-27-13 preparation (Fig. 3, FIg. 4), so that is 
what is given here. 
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2.3.3 Cell lysis, Ni-NTA column purification and CFD buffer exchange  
 
20. Thaw cell pellets for 15 minutes at RT, then place on ice. Add 40 mL ice-
cold resuspension buffer with protease inhibitors (NPI-10+PIs, see Table 1) 
to each 250 mL bottle, and resuspend by vortexing and/or pipetting up and 
down. Incubate on ice 30 minutes before lysing cells. 
21. Transfer each cell suspension to a pre-chilled 50 mL conical tube. Lyse the 
cells using a French press (Fig. 1), maintaining ~900-1000 psi, (Fig. 1G) 
and running each sample through the press 3x at a dropwise rate (Fig. 1F). 
Collect the lysate with a clean pre-chilled 50 mL tube each time. Detailed 
steps are as follows: 
i. Inspect the components, especially the O-rings on the cap and piston 
(Fig. 1A-iv, -v) and the plastic flow valve seat bead (Fig. 1B). 
Replace if noticeably damaged. 
ii. Check the press itself. If it’s not lowered all the way, turn the 
hydraulic pump on, select DOWN (Fig 1G-i, -ii), wait until it’s 
lowered, then turn the pump off (it's best not to let the pump run 
when it’s not in motion). Open the safety bar if it’s in the way. 
iii. Screw the outlet nozzle into the cylinder and finger-tighten. Also 
screw in the flow valve and gently ensure that it is closed, but do not 
overtighten, as that will deform the plastic bead (Fig. 1B). 
iv. Insert the piston into the cylinder, and place the assembly into the 
inverted filling stand. Either prop the piston or hold it to prevent it 
from falling out, if necessary (Fig. 1C). 
v. Pour ~40 mL cell suspension into the cylinder and put the cap on the 
cylinder. Note that this will create internal pressure and push the 
piston out slightly (with the valve closed, as it should be) or eject cell 
suspension from the outlet (with the valve open). 
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vi. Holding the capped end of the cylinder with one hand and the piston 
with the other, invert the assembly and place it into the press. Close 
the safety bar and tighten at least one of the set screws (Fig. 1D-ii).  
vii. If necessary, turn the piston handle such that it won’t contact the 
safety set screw when the press is fully compressed (Fig. 1E). Gently 
ensure the flow valve is closed, but don’t overtighten. 
viii. Begin raising the press ram by turning on the pump and selecting 
MED, then immediately check the pressure reading (Fig. 1G-i, -ii, -
iii). If it is extremely higher or lower than ~450, adjust the knob (Fig. 
1G-iv). Very soon, the top of the press will contact the piston and 
begin to apply pressure.  
ix. Prepare to collect the lysate by holding the clean, pre-chilled 50 mL 
tube as shown (Fig. 1F).  
x. Open the flow valve slowly and begin collecting lysate at a dropwise 
rate. Check the gauge pressure again, and adjust it with the knob 
again, if necessary.  
xi. Maintain dropwise collection. The valve position needed for this will 
vary during operation. Be prepared for a sputter of debris-ridden 
lysate at the end of the press cycle. 
xii. Repeat 2x for each ~40 mL cell suspension (3 press cycles total), 
collecting in a clean, pre-chilled 50 mL tube each time. 
Ø CRITICAL: Keep lysates on ice as much as possible. Also, chill the 
cylinder assembly on ice for ~10-15 minutes before lysing the next ~40 mL 
cell suspension. 
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Figure 1. Lysis of bacterial cultures with a French press  
A) French press components requiring assembly: i) cylinder; ii) flow valve; iii) 
outlet nozzle; iv) cylinder cap; v) piston. B) Plastic valve seat bead must be 
replaced if deformed, or the valve will not fully close. C) Press components semi-
assembled on the inverted stand, ready to add cell suspension. The piston must 
be propped or manually held to prevent it from falling out when the cap is put on. 
D) Assembled press. (i) Turn the piston handle 90° from position shown, and (ii) 
tighten at least one of the safety set screws. E) Piston at lower limit of travel; note 
the handle orientation prevents contact with the safety screw. F) During press 
operation, adjust valve to keep a dropwise flow rate. G) Press control panel: i) 
Press operating lever. The “DOWN” position lowers the hydraulic ram, while 
“MED” compresses the piston. Do not use the “HIGH” setting. ii) Gauge pressure 
reading for maintaining ~900-1000 psi cell pressure11. iii) Hydraulic pump on/off 
switch. iv) Pressure adjustment knob. 
 
 
 
 
 
                                                
11  The chart on the control panel indicates a gauge pressure of 482 equals 1000 psi cell 
pressure, using the 1” diameter piston and selecting the MED ratio. 
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22. Clear the cell lysate by centrifugation at 5,000 x g at 4°C for 1-2 hours12. 
This pellets the majority of cellular debris, and the insoluble protein fraction. 
23. When centrifuging is complete, remove any floating cellular debris from the 
tubes of cell lysate with a P1000 micropipette. 
24. Further clear the cell lysates by filtering with 5 µm syringe filters. Several 
syringe filters may be required per 50 mL lysate, as they clog up with debris. 
Save the insoluble pellet at -80°C, as it may be needed for troubleshooting. 
Ø CRITICAL: Depress the syringe slowly to minimize foaming, as this can 
denature proteins. 
25. Set up the Ni-NTA Superflow column and purification rack in a 4°C room. 
Ø CRITICAL: Always use a new column for each purification batch. In my 
hands, column reuse had undesirable downstream effects on purity. 
26. Check that the bluish Ni-NTA resin is settled properly in the Superflow 
column (Fig. 2A-ii). If it was not properly stored upright, bluish resin will be 
visible in the column filling chamber (Fig. 2A-i). Let the column stand 
vertically in the rack until the resin is settled, if necessary.  
27. Cut the tip of the column to open the outlet (Fig. 2A-iii). 
28. Remove the white cap, and allow the storage buffer to drain by gravity flow 
(Fig. 2B) or apply mild vacuum pressure (Fig. 2C). 
Ø CRITICAL: Never let the column run dry while applying vacuum pressure. 
Instead, remove the vacuum tubing and allow the column to finish draining 
by gravity flow. The column will not run dry by gravity flow. 
29. Equilibrate the Ni-NTA column with 10 mL pre-chilled resuspension buffer 
(NPI-10+PIs), and allow the column to drain by gravity flow. 
30. Transfer ~10 mL cleared lysate to the Ni-NTA column loading reservoir. 
Allow to drain by gravity flow (Fig. 2D). Continue to add the rest of the 
                                                
12 The Bardwell Lab JA-17 rotor with ‘partially supported’ 50 mL conical tubes limits this 
spin to 5,000 x g, or 4,000 rpm. Otherwise, higher speeds could be used. 
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cleared lysate13. Collect several drops of column outflow at least once 
during this step (and steps 31-32) for later analysis. Sampling of additional 
time points may help with any troubleshooting that may be necessary. 
31. Wash with 2 x 10 mL buffer NPI-20+PIs. Apply mild vacuum pressure 
and/or allow the column to drain completely by gravity flow. 
32. Perform an additional stringent wash by adding 5 mL buffer NPI-80+PIs. 
Apply mild vacuum pressure and/or allow the column to drain completely by 
gravity flow. 
33. Elute the bound NSD3-SET by adding 3 mL buffer NPI-250+PIs, collecting 
the flow-through in a clean 15 mL conical tube. Allow the column to drain 
completely by gravity flow. 
34. Perform a second elution by adding another 3 mL buffer NPI-250+PIs, and 
collecting in a new tube. Allow to drain completely by gravity flow. 
35. Allow the eluates to reach RT by incubating ~10 min on the bench. Transfer 
the first and second eluate (E1, E2) each to a 30 kDa MW cutoff 
MicroSep™ centrifugal filter device (CFD).  
36. Centrifuge E1 and E2 at 2,000 rpm for 15-30 minutes. The sample volumes 
should be reduced to 0.5-1 mL, with E2 the lower of the two, due to a lower 
NSD3-SET concentration. Empty the lower collection tubes of the CFDs. 
Add imidazole-free buffer (50 mM Tris pH 9.0, 5 mM MgCl2, +PIs) to fill the 
upper part of the CFD (to 5 mL). 
37. Repeat the previous step approximately three times. Track the volume of 
the concentrated eluates after each spin and the volume of fresh buffer 
added. Be careful not to over-concentrate the first elution, which contains 
the majority of the purified NSD3-SET. 
                                                
13 The 1.5 mL of Ni-NTA resin in the column has a binding capacity of 75 mg, which is 
more than enough to accommodate the expressed protein from 1.5 L total culture 
volume. Thus, ~80 mL of cleared lysate (total) is allowed to flow through a single 
column.	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Ø CRITICAL: Inspect the concentrated eluates carefully (especially E1) after 
each spin for signs of precipitation. If cloudiness is present near the bottom 
of the filter cartridge, and buffer exchange is incomplete, add 1-2 mL fresh 
buffer and pipet mix before centrifuging again.  
38. Buffer exchange is complete when the two 3 mL eluates have been diluted 
1:50 or better. (An imidazole concentration of 5 mM is acceptable, as the 
preparation will be diluted in a MTase assay.) 
39. Centrifuge one final time to concentrate the sample, if necessary, and 
remove the sample with a syringe. 
Ø CRITICAL: Minimize foaming when withdrawing the sample with a 
syringe, as this can denature proteins. 
40. Aliquot as desired, snap-freeze in liquid N2, and store at -80°C14. A small 
aliquot (~5 µl) may be kept on ice for immediate testing with the MTase 
assay, and/or other quality control testing (see below). 
§ PAUSE POINT: It was determined that NSD3-SET MTase activity rapidly 
declines within 2-4 weeks when purified under these conditions. Thus, 
quality control testing and downstream experiments (i.e., ProtoArray®) 
should be performed as soon as possible. 
41. Determine the concentration of the NSD3-SET purified preparation with the 
Qubit Protein Assay, according to the manufacturer’s instructions. 
42. Perform SDS-PAGE followed by Coomassie staining to assess final NSD3-
SET sample purity, and the efficiency of the column purification, if desired.  
 
 
 
 
                                                
14 Storage of NSD3-SET in liquid N2 may increase the shelf life of its MTase activity, 
though this possibility remains untested. 
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Figure 2. Ni-NTA Superflow column purification 
A) The Ni-NTA Superflow column: i) 10 mL column loading reservoir; ii) column 
packed with 1.5 mL Ni-NTA resin; iii) column outlet (cut at arrow); iv) column 
filling chamber neck, note the bluish Ni-NTA resin has already migrated from the 
column after being held at an angle for ~30 seconds. B) View from below the 
column while in the purification rack, with equilibration buffer (NPI-10+PIs) 
flowing out dropwise by gravity flow. C) Assembled apparatus for applying mild 
vacuum pressure15 to the column to increase flow rate: latex tubing, a 10 mL 
serological pipette and a Pipet-Aid®. Apply pressure with the Pipet-Aid® such 
that the column loading reservoir is near-empty in approximately 4 minutes (or 
longer). DO NOT let the column run dry under vacuum pressure. D) Column 
loaded with cleared lysate. 
 
 
 
 
 
                                                
15  Ni-NTA Superflow column recommended vacuum pressure is -10 mbar, while the 
recommended flow rate is 1-3 mL/minute (QIAexpressionist, Qiagen 06/2003). 
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2.4 Procedure: in vitro methyltransferase assay with purified NSD3-SET 
 
43. Set up each 20 µl MTase assay reaction as given below. Typically, use 2 µl 
(20 nM final concentration) for the histone H3 positive control enzyme 
complex PRC (Simon Lab). For initial testing of purified NSD3-SET, test 
three enzyme concentrations (i.e., 100 nM, 200 nM, 400 nM). If testing 
substrates other than polynucleosomes, start with 500 ng substrate per 
reaction. First, assemble all reaction components, except the tritiated SAM. 
10 µl 2X MTase buffer 
2 µl polynucleosomes (1 mg/mL) 
X µl KMT (NSD3-SET, or positive control PRC) 
X µl sterile distilled H2O (to 20 µl) 
1 µl 3H-SAM (0.001 mCi) 
44. Move behind the plastic shield in the radioactivity area. Add the 1 µl tritiated 
SAM to each reaction. 
45. Incubate the reactions for 1-1.5 hours in a 30°C heat block. Meanwhile, 
pour a 4-15% SDS-PAGE gel. 
46. Stop the MTase reactions by adding 5 µl 4x SDS sample buffer to each. 
47. Load each full reaction in the gel (Step 45), and electrophorese for 1 hour at 
30 mA. 
48. Remove gel from the running apparatus and place it in Towbin transfer 
buffer. Incubate at RT for at least 15 minutes. Meanwhile, dispose of all 
radioactive waste properly, and prepare the Immobilon-P membrane for 
transfer. 
49. Cut the Immobilon-P membrane to size. Place it methanol for 15 seconds. 
Transfer into distilled H2O for 2 minutes (do not submerge). Place 
membrane in Towbin buffer for at least 5 minutes. 
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50. Prepare the transfer stack. Soak filter paper in Towbin buffer. Build the 
stack from the bottom up: filter paper, Immobilon-P membrane, gel, and 
filter paper. Roll out any air bubbles. 
51. Transfer at 20V for 20-30 minutes. When done with the transfer, place all 
components of the stack (except the membrane) in the tritium solid waste. 
52. Allow the membrane to dry for 1-5 minutes. Place it into Amido Black Stain, 
which allows visualization of all transferred proteins. Incubate at RT for 5 
minutes. 
53. Transfer membrane to 100% methanol. Wash quickly 3x to remove the 
excess Amido Black stain. 
54. Tape the membrane down to a large piece of filter paper. 
55. In the fume hood, spray the membrane with EN3HANCE spray. Cover 
completely, but try not to saturate. Allow the membrane to dry, which takes 
10-15 minutes. 
56. Rotate the filter paper with attached membrane 90°, and spray again. 
Repeat two more times, such that the membrane has been sprayed in all 
four orientations. 
57. Place the membrane in a cassette (preferably the same one which is always 
used for MTase assays—as the EN3HANCE spray has an unpleasant odor). 
Tape it down, along with a piece of filter paper with luminescent writing on it, 
which serves as a fiducial marker. 
58. In the darkroom, place a single-sided film emulsion side-down on the 
membrane. Do not use intensifying screens. Expose the film overnight at -
80°C, or for up to a week. 
59. Develop film while it is still frozen; do not let it thaw. A new film may be 
exposed for a week or longer, if a shorter exposure has already been 
completed. 
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60. For final clean-up, take Q-tip smears of pipettors, the bench in various 
places, the shaker, and anything possibly contaminated with radioactivity. 
Place the smears in 3 mL scintillation fluid in a scintillation vial, and count 
against a blank on an open window in the scintillation counter. 
Decontaminate with Lift-Away as necessary. 
61. Log the volume of 3H-SAM used and from which aliquot. Also, log the 
amount of radioactive waste as follows: 5% solid waste (0.00005 mCi); 95% 
liquid waste (0.00095 mCi). 
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2.5 Anticipated results 
 This optimized procedure yields ~900 µg of >90% pure N-terminally 6xHis-
tagged NSD3-SET (Fig. 3), which methylates histone H3 of polynucleosome 
substrate in an in vitro methyltransferase assay (Fig. 4). While early 
permutations of the procedure also yielded catalytically active NSD3-SET (Fig. 4, 
purified 3-27-13), the protocol detailed here achieves NSD3-SET purity and 
yield that is suitable for non-histone target discovery via the ProtoArray® (Life 
Technologies Technical Staff, personal communication). However, the weak 
activity of NSD3-SET (as compared to the robust H3 methylation catalyzed by 
Drosophila PRC), and the very short period in which NSD3-SET retains even this 
low level of MTase activity (1-2 weeks, data not shown) raises several concerns.  
First, a key consideration is whether a large fraction of bacterially-
expressed NSD3-SET consists of misfolded proteins or aggregates, leading to its 
observed lackluster MTase activity. Native PAGE and/or high-resolution size 
exclusion chromatography, such as with a Superdex 200 column, could rule this 
out and ensure purified NSD3-SET homogeneity (GE Healthcare Life Sciences). 
However, it is important to note that bacterially-expressed human NSD3-SET 
also showed weak histone H3 methylating activity, despite an extra cleanup or 
‘polishing’ step with a Superdex 200 column and pooling of the resulting samples 
(Li et al., 2009). Indeed, this is in keeping with the mounting evidence for NSD3 
as a KMT with additional, non-histone substrates in vivo (1.3). 
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A second significant drawback to NSD3-SET purified in this manner is its 
loss of catalytic activity within a few weeks, thus rendering the successive testing 
of individual candidate substrates (such as chick EF1α1) somewhat impractical. 
Although this short KMT shelf life also complicates the logistics of candidate 
target discovery with ProtoArray® methyltransferase substrate profiling, it does 
not negate such an array-based experiment's potential as a critical step toward 
revealing novel, non-histone substrates of NSD3, if any. 
Importantly, a thorough kinetic characterization of human NSD catalytic 
fragment activity in vitro was recently published, which revealed that the use of 
TCEP instead of DTT as the disulfide reducing agent resulted in a six-fold 
increase in NSD3-SET activity on polynucleosomes (Allali-Hassani et al., 2014). 
However, a different MTase assay was used than the method described here, 
and TCEP was also the reducing agent in buffers throughout their purification 
procedure. Therefore, it is unclear whether simply using TCEP instead of DTT in 
the reaction buffer will achieve the same dramatic improvement in chick NSD3-
SET methylation of polynucleosomes. Furthermore, TCEP is not particularly 
stable in sodium phosphate buffers (Thermo Fisher Scientific), so making full use 
of this insight may require re-optimization of the procedure. 
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Figure 3. Purification of chick NSD3-SET has been optimized to >90% 
purity. Peptide contaminants (asterisks) were found in the low-yield NSD3-SET 
preparation purified 3-27-13 (previously active in a MTase assay), and were even 
more prominent in later scaled-up preparations. The purification procedure was 
then optimized for high yield (>900 µg) at greater than 90% purity (purified 12-27-
13). 
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Figure 4. Purified chick NSD3-SET is active in a methyltransferase assay. 
After optimizing recombinant chick NSD3-SET purification for large-scale culture 
in bacteria, methyltransferase activity on histone H3 (arrowhead; all lanes) was 
restored (purified 12-27-13; lanes 3 & 4), although it is very weak compared to 
Drosophila PRC complex (lane 5) and rapidly declines. Previously-active NSD3-
SET purified 3-27-13, no longer shows detectable activity (lanes 1 & 2). 
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